# A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Source: https://onco.cc/trials/nct05967689/  
OnCo record `nct05967689` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TAS6417 in non-small-cell lung cancer, run by Taiho Oncology, Inc., now recruiting.

## Summary

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. is a phase 2 interventional study registered as NCT05967689 by Taiho Oncology, Inc., with 220 participants planned, started 2023-07-31 and due to reach its primary completion in 2028-08-31. Interventions recorded: TAS6417, CYP Cocktail and Transporter Cocktail.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05967689
- Phase: 2
- Setting: An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
- Sponsor: Taiho Oncology, Inc.
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT05967689: https://clinicaltrials.gov/study/NCT05967689

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/)

---
JSON: https://onco.cc/api/v1/entities/nct05967689.json